|Bid||0.0740 x N/A|
|Ask||0.0800 x N/A|
|Day's range||0.0640 - 0.0790|
|52-week range||0.0100 - 0.1300|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Lumos Diagnostics Holdings ( ASX:LDX ) Full Year 2023 Results Key Financial Results Revenue: US$10.5m (down 9.4% from...
Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to market its FebriDx® rapid, point-of-care test in the United States.